Hypoxia- and radiation-induced overexpression of Smac by an adenoviral vector and its effects on cell cycle and apoptosis in MDA-MB-231 human breast cancer cells

WEI-WU LIU1,2*, YANG LIU1, SHUO LIANG1, JIA-HUI WU1, ZHI-CHENG WANG1 and SHOU-LIANG GONG1

1Key Laboratory of Radiobiology, Ministry of Health, School of Public Health, Jilin University, Changchun, Jilin 130021; 2Department of Radiology, Second Hospital, Jilin University, Changchun, Jilin 130041, P.R. China

Received August 8, 2013; Accepted October 10, 2013

DOI: 10.3892/etm.2013.1351

Abstract. A conditionally replicative adenoviral (CRAd) vector, designated as CRAd.pEgr-1-Smac, that promotes the overexpression of second mitochondria-derived activator of caspase (Smac) when stimulated by hypoxia and radiation, was constructed. MDA-MB-231 cells were transfected with CRAd.pEgr-1-Smac and treated with 4-Gy X-rays. The hypoxic status in cancer cells was mimicked with the chemical reagent CoCl2. Smac protein expression was measured by a western blotting assay and cell proliferation was detected with the MTT assay. The cell cycle progression and apoptotic percentage were measured by flow cytometry with PI and Annexin V-FITC staining kits, respectively, following the irradiation of the transfected cells with 4-Gy X-rays. The results showed that CRAd.pEgr-1-Smac was able to increase the Smac protein expression induced by hypoxia and radiation, inhibit cell proliferation and promote apoptosis. Therefore, this method of gene-radiotherapy is indicated to be an ideal strategy for the treatment of breast cancer.

Introduction

Breast cancer accounts for 30% of primary malignant tumors in women (1). Radiotherapy is an important method for the clinical treatment of breast cancer, but its curative effect is often affected by damage to the surrounding normal tissues and tumor radiation tolerance, so radiotherapy alone has certain limitations (2). Gene-radiotherapy, as a new therapy that combines gene therapy and radiation therapy, has attracted much interest and has broad application prospects (3,4). The basic principle of gene-radiotherapy is the use of the radiation-induced characteristics of early growth response-1 (Egr-1) to increase the expression of a target gene following radiation and thereby enhance the treatment effect. Egr-1, containing the six serum response elements of CArG [CC (A + T-rich) 6GG], is a key component of radiation-activated expression. Numerous studies have observed that if the Egr-1 promoter gene is placed upstream of TNF-α, IFN-γ, endostatin and TRAIL genes, it promotes the expression of these genes by radiation induction (5-7). In the present study, the application of the radiotherapy-induced Egr-1 promoter gene is considered.

The target gene of tumor gene-radiotherapy may be a pro-apoptotic, cytokine or suicide gene (7-9). Ionizing radiation is able to induce the apoptosis and cell cycle arrest of tumor cells, and the failure to repair DNA damage following cell cycle arrest causes cell apoptosis (10). Therefore, second mitochondria-derived activator of caspase (Smac) was used as the target gene in the current study. Smac is localized in the mitochondria and released into the cytoplasm, triggering a cascade reaction of the caspase family through a variety of pathways, and promoting apoptosis. Smac is expressed in a variety of tumors, and is closely associated with the occurrence and development of various tumors (11). The overexpression of the Smac gene may promote the apoptosis of tumor cells and enhance the sensitivity of the cells to chemotherapy and radiotherapy. A previous study has shown that overexpression of the Smac gene may cause cancer cells to become more sensitive to apoptotic stimuli. In particular, a short amino acid sequence, which is separated from the N-terminus of the Smac protein, also reacts with XIAP and may kill tumor cells overexpressing IAPs (12,13). The purpose of the current study was to investigate the dual effects of apoptosis induced by ionizing radiation and the Smac gene.

Egr-1 may be activated by radiation to deliver gene therapy, but often the hypoxic microenvironment in solid tumors markedly reduces the effect of the Egr-1 promoter. Overcoming solid tumor hypoxia (leading to radiation tolerance) is a key challenge in the treatment of tumors. The core sequence of hypoxia response elements (HREs), 5'-T(A/G)CGT(G/C)(G/C)-3', has clear hypoxia-inducible characteristics (14-16). In addition, the use of specific replication with the conditionally
replicative adenovirus (CRAd) in tumor cells is able to greatly increase the copy number and cause the high level expression of therapeutic genes (17). The conditionally replicative adenovirus mediated by HREs may achieve increased gene expression under hypoxic conditions and overcome the low efficiency of radiotherapy caused by the hypoxic environment.

Therefore, in the present study, HRE and Egr-1 were used to construct a CRAd vector to mediate the expression of the Smac gene when induced by the dual stimuli of hypoxia and radiation. The effects of the vector on the proliferation, cell cycle and apoptosis of MDA-MB-231 human breast cancer cells were then observed. This exploration of the gene-radiotherapy effect was conducted in order to provide new insight for the clinical radiotherapy of breast cancer.

Materials and methods

Cell lines and culture. MDA-MB-231 human breast cancer cells were purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Science (Shanghai, China). The cells were cultured at 37°C with 5% CO2, using L15 medium containing 10% fetal bovine serum, 100 U/ml penicillin and streptomycin (Gibco BRL, Carlsbad, CA, USA). HEK293 human embryonic kidney cells were maintained by the Institute of Biochemistry and Cell Biology, Chinese Academy of Science (Shanghai, China). The cells were cultured under the same conditions as were used for the MDA-MB-231 cells, with a high sugar DMEM medium containing 10% fetal bovine serum, 100 U/ml penicillin and 100 U/ml streptomycin (Sigma, St. Louis, MO, USA).

CRAd. A shuttle vector, pShuttle-Egr-1-Smac-HRE-hTERT-E1A-E1Bp-E1B55K was constructed. It was activated by hypoxia and radiation, resulting in the overexpression of Smac. The shuttle vector was transferred into BJ5183 (AdEasy-1+) by electroporation, where it underwent homologous recombination with pAdEasy-1 to form the recombinant adenovirus plasmid. The plasmid was then transfected into HEK293 cells using the Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). After packing, the CRAd was named CRAd.pEgr-1-Smac. The empty virus CRAd.p served as the control. After 3-5 generations of amplification, the virus was collected, the virus titer was confirmed by determining the 50% tissue culture infection dose (TCID50) and the virus was stored below -70°C. The establishment process of pShuttle-Egr-1-Smac-HRE-hTERT-E1A-E1Bp-E1B55K is shown in Fig. 1.

Cell transfection, hypoxia and X-ray irradiation. The MDA-MB-231 cells were divided in six groups: normal control, CRAd.pEgr-1-Smac, hypoxia (H), empty virus (CRAd.p), CRAd.pEgr-1-Smac + H and CRAd.p + H. Briefly, the cells were seeded in 6-, 24- or 96-well culture plates. As the cells reached 80-90% confluence, they were infected with the adenovirus at a MOI [multiplicity of infection (virus/cell)] of five for 24 h according to the literature method (18). CoCl2 (Sigma) was added at a final concentration of 150 µmol/l for 24 h to simulate hypoxia (19). The X-ray irradiation was performed using an X-ray machine (X.S.S.250FZ, Guiyang Medical Instrument, Guiyang, China) under the following conditions: 200 kV, 10 mA, 0.5 mm Cu filter and 1.0 mm Al filter, a target skin distance of 50 cm, and 0 or 4 Gy of radiation at a dose rate of 0.287 Gy/min. The dose and dose rate options were in accordance with studies by the United Nations Scientific Committee on Atomic Radiation (UNSCAR) in 1986 and our previous work (7,20).

Detection of the Smac protein. The MDA-MB-231 cells were seeded at a density of 1x10⁶ cells in each well of 6-well culture plates, followed by the treatment described in the preceding section. The cells were collected 24 h after irradiation and lysed using a lysis buffer (10 mmol/l Tris-HCl, pH 7.4; 1 mmol/l EDTA, pH 8.0; 0.1 mol/l NaCl; 1 µg/ml aprotinin; 100 µg/ml phenylmethanesulfonyl fluoride (PMSF)). The total protein was extracted, quantified using a Coomassie blue protein quantification kit (Nanjing Jiancheng Biological Institute, Nanjing, China) and separated by 12% SDS-PAGE (loading: 50 µg). The protein was electroblotted onto a nitrocellulose membrane. Then, the membrane was incubated consecutively in 5% nonfat milk for blocking for 1 h and with anti-GAPDH or anti-Smac antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) overnight at 4°C. The membrane was then washed in TBST buffer and incubated with horseradish peroxidase-conjugated secondary antibody at 37°C for 1 h (Thermo Fisher Scientific Inc., Lake Barrington, IL, USA). The western blotting luminal reagent (Santa Cruz Biotechnology, Inc.) was used to develop the blots, followed by the photographic capturing of images for analysis.

Detection of cell proliferation. The 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) method was used to detect cell proliferation. Briefly, the MDA-MB-231 cells were seeded at a density of 2x10⁴ cells per well in a 96-well culture plate, with six replicates for each group, and treated as described previously. At 12, 24 and 48 h after irradiation, 10 µl MTT (5 mg/ml; Sigma) was added for 4 h. The supernatants were discarded and 100 µl dimethylsulfoxide (DMSO; Sigma) was added to dissolve the crystals. The optical density (OD) value at 570 nm was measured using a microplate reader (Bio-Rad, Hercules, CA, USA) (7). The experiment was repeated three times.

Flow cytometric analysis of the cell cycle and apoptosis. The cell cycle and apoptosis were analyzed by flow cytometry...
(FCM; Becton-Dickinson, Franklin Lakes, NJ, USA) with PI single dye (Sigma) or PI + Annexin V-FITC double staining (Nanjing KeyGEN Biotech Co., Ltd., Nanjing, China), respectively. Briefly, the MDA-MB-231 cells were seeded at a density of 3x10^5 cells per well in 24-well culture plates, and treated as described previously. Cells were collected in an Eppendorf tube 24 h after irradiation and washed twice with PBS by centrifugation. The supernatants were discarded. To analyze the cell cycle, 50 µl RNase A and 200 µl PI were added to each tube, and the tube contents were mixed in the dark at room temperature for 20 min, followed by FCM testing. To detect apoptosis, 500 µl PBS, 5 µl Annexin V-FITC and 5 µl PI were added to each tube, and the contents of the tube were mixed in the dark at room temperature for 15 min, followed by FCM testing. Cell Quest software (Becton-Dickinson) was used to acquire and analyze the data, and the data are expressed as cell percentages.

**Statistical processing.** The experimental data are expressed as mean ± standard deviation (SD). A one-way ANOVA test was used for statistical analysis using the statistical software SPSS 12.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant result.

**Results**

Expression of Smac protein in MDA-MB-231 cells. At 6, 12 and 24 h after sham irradiation (0 Gy), the difference in Smac protein expression between groups was small, which indicated that the Egr-1 promoter had no function in the absence of irradiation and was unable to express the characteristic of regulating the downstream gene (Fig. 2). At 6 h after 4-Gy irradiation, there was no significant increase in the level of Smac expression; while after 12 and 24 h, the Smac expression level was increased in the CRAd.pEgr-1-Smac and CRAd.pEgr-1-Smac + H groups, particularly in the latter.

Changes in cell proliferation. As shown in Fig. 3, at 6 h after 0- and 4-Gy X-ray radiation, hypoxia inhibited the growth of MDA-MB-231 cells; there was a statistically significant difference in cell proliferation between the hypoxia and normal control groups (P<0.01). At 12 h, the transfected virus also inhibited MDA-MB-231 cell growth, and the inhibition was time-dependent. At 6 h after 4-Gy irradiation, there was no significant reduction in the proliferation of the cells transfected with the CRAd.pEgr-1-Smac virus, while the proliferation was reduced significantly following hypoxia (P<0.01). At 12 h, the cell proliferation of each group decreased significantly (P<0.01), and at 48 h, it reached minimum values.

Changes in MDA-MB-231 cell cycle progression. Apoptosis occurs in various cell cycle phases, and cell cycle progression and apoptosis are closely associated. As shown in Fig. 4, the transfection with CRAd.pEgr-1-Smac or CRAd.p in combination with hypoxia may lead to an increase in the percentage of MDA-MB-231 cells in the S phase. The CRAd.pEgr-1-Smac + H and CRAd.p + H groups had a significantly increased percentage of cells in the S phase compared with the control group (P<0.01), and a significantly increased percentage of cells in the G2/M phase compared with the normal control group (P<0.05). The 4-Gy irradiation and hypoxia led to increases in the percentages of cells in the S and G2/M phases, while transfection with CRAd.pEgr-1-Smac did not change the cell cycle markedly. The 4-Gy irradiation of normal control cells increased the percentage of cells in the S and G2/M phases significantly compared with 0-Gy irradiation (P<0.05), while no significant changes occurred in the other groups.

Changes in apoptosis of MDA-MB-231 cells. In Figs. 5 and 6, transfection with CRAd.pEgr-1-Smac and hypoxia following 0-Gy irradiation is shown to induce MDA-MB-231 cell apoptosis significantly when compared with the normal control.
transfection with CRAd.p had no such effects, but when combined with hypoxia was able to induce cell apoptosis significantly (P<0.01). When treated with 4 Gy of radiation, the cell apoptosis events in each group were the same as those when 0 Gy of radiation was used. The CRAd.pEgr-1-Smac + H group presented the greatest increase in cell apoptosis. In addition, in this group, the percentage of cell apoptosis when 4 Gy of radiation was administered was significantly higher compared with that when 0 Gy of radiation was used (P<0.01).

Discussion

The efficient expression of radiation-inducible therapeutic genes in tumor cells is crucial in gene-radiotherapy. Only by the overexpression of the gene with its corresponding functions may the combined effects of gene therapy and radiotherapy be achieved. CRAd, also called oncolytic adenovirus, is an ideal expression vector, which is able to replicate in tumor cells and produce a cascade effect (21,22). Relevant studies (5-7,23) have confirmed that ionizing radiation is able to induce the Egr-1 promoter to activate the expression of the downstream gene, which generates oxygen-free radicals acting on the six serum response element CArG. Hypoxia in solid tumors leads to the reduction of the free radicals induced by radiation, affecting the efficiency of the Egr-1 promoter.

The present study used the hypoxia-inducible characteristic of HRE to enhance the replication ability of CRAd under hypoxic conditions, and also strengthened the mediated efficiency of radiation on the Egr-1 promoter, increasing the expression of Smac, and thus realized dual activation by radiation and hypoxia.

At 6, 12 and 24 h after sham irradiation (0 Gy), the difference in Smac protein expression between the groups was small, indicating that the Egr-1 promoter had no function in the absence of irradiation, and was not able to regulate the downstream gene. The presence of Smac expression observed in each group may be due to endogenous expression in the cell, not the exogenous Smac expression. At 6 h after treatment with 4 Gy of radiation, there was no significant increase in Smac expression, while after 12 and 24 h, Smac expression was increased in the CRAd.pEgr-1-Smac group, and markedly increased in the CRAd.pEgr-1-Smac + H group. These results indicated that radiation activated the Egr-1 promoter. Hypoxia induced an increase in the replication of CRAd, suggesting that this experiment achieved the targeted overexpression of the therapeutic Smac gene with radiation and hypoxia.

At 12 h after 0-Gy irradiation, the transfected virus inhibited the MDA-MB-231 cell growth, and the inhibitory effect was time-dependent. This was likely due the CRAd itself being able to inhibit the tumor cell proliferation (24). At 6 h after 4-Gy irradiation, there was no significant reduction in the proliferation of the cells transfected by the CRAd.pEgr-1-Smac virus, while the proliferation reduced significantly following hypoxia (P<0.01). At 12 h, the cell proliferation of each group decreased significantly (P<0.01), and at 48 h, the proliferation reached minimum values. These results indicate that the expression of Smac protein was at a low level 6 h after irradiation and had no function. With the progression of time, the expression level increased and Smac was able to fully inhibit cell proliferation.

After exposure to ionizing radiation, most cells are in G2 arrest, ensuring the DNA damage is repaired and conducive to cell survival (25). Furthermore, G2 arrest is also associated with cell radiosensitivity and may increase cell radiosensitivity, which is useful in the radiation therapy of tumor cells (26). The changes in MDA-MB-231 cell cycle progression demonstrate that the conditions in the present study maintained the MDA-MB-231 cells in G2/M phase arrest, which may increase the cellular radiosensitivity and aid tumor radiotherapy.

The aim of tumor gene-radiotherapy includes not only the inhibition of cell proliferation, but also the induction of cell death. Apoptosis is one type of cell death. Ionizing radiation is the basis of clinical radiotherapy, which is able to induce tumor cell apoptosis directly and block the cell cycle

![Figure 5. Flow cytometric detection of the apoptosis of MDA-MB-231 cells after 0- and 4-Gy X-ray radiation. Smac, second mitochondria-derived activator of caspase; CRAd, conditionally replicative adenovirus.](image)

![Figure 6. Change in the apoptotic percentage of MDA-MB-231 cells after 0- and 4-Gy X-ray radiation.](image)
checkpoint. Initiating apoptosis by using certain radiotherapy strategies may inhibit the growth of tumor cells effectively, being quite important to tumor radiotherapy. Smac is one type of apoptosis-inducing factor. An anti-tumor study conducted with Smac in recent years indicated that the overexpression of Smac may cause tumor cell apoptosis, and increase the sensitivity of tumor cells to chemotherapy (27). The increase in apoptosis of MDA-MB-231 cells with Smac overexpression suggests that when the cells transfected with CRAd.pEgr-1-Smac are in a hypoxic condition, treatment with ionizing radiation is able to induce the highest level of cell apoptosis. Therefore, the present study indicates that the maximum efficacy may be achieved by using the gene-radiotherapy strategy.

In conclusion, this study achieves the overexpression of Smac with hypoxia and radiation; its ability to inhibit cell proliferation and induce the apoptosis of MDA-MB-231 breast cancer cells is clearly apparent. The overexpression of Smac may also result in cell cycle arrest by enabling the G2/M phase, i.e. the radiation-sensitive cell cycle phase, which is also likely to facilitate the subsequent radiotherapy. This study explored a gene-radiotherapy strategy for treating breast cancer, and this strategy is expected to solve gene selection and targeting problems. First, the hypoxic microenvironment of solid tumors was used to overcome the ineffectiveness of gene-radiotherapy caused by hypoxia. Secondly, the CRAd vector was used to deliver a therapeutic gene to tumor cells subjected to increased radiation levels and a hypoxic status. Radiotherapy may be fully integrated with the favorable and unfavorable conditions of genes to maximize the benefits of radiotherapy. This study provides a new method for the clinical treatment of breast cancer.

Acknowledgements

This study was supported by the National Natural Science Foundation No. 30870747 and No. 30970681.

References

1. DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 61: 409-418, 2011.
2. Kwong DL, Sham JS, Leung LH, Cheng AC, Ng WM, Kwong PW, Lui WM, Yao CC, Wu PM, Wei W and Au G: Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 64: 374-381, 2006.
3. Zheng AQ, Song XR, Yu JM, Wei L, and Wang XW: Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice. World J Gastroenterol 11: 4439-4442, 2005.
4. Harari PM and Huang SM: Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 49: 427-433, 2001.
5. Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP and Wang JH: Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Ann Surg Oncol 16: 1403-1411, 2009.
6. Yang W and Li XY: Anti-tumor effect of pEgr-interferon-gamma-encoding adenovirus in mice bearing Lewis lung carcinoma and its mechanism. Chin Med J (Engl) 118: 296-301, 2005.
7. Li Y, Guo C, Wang Z, Gong P, Sun Z and Gong S: Enhanced effects of TRAIL-endostatin-based double-gene-radiotherapy on suppressing growth, promoting apoptosis and inducing cell cycle arrest in vascular endothelial cells. J Huazhong Univ Sci Technol Med Sci 32: 167-172, 2012.
8. Wu C, Li X and Tian M: Effect of pEgrTNFalpha gene radiotherapy on mice melanoma. Melanoma Res 15: 185-190, 2005.
9. Zhang Y, Yu XH, Zha X and Kong W: Adenovirus-mediated HSV-TK gene therapy using an ITERT promoter in CNE cells in vitro. Chem Res Chinese Universities 25: 60-63, 2009.
10. Wang WD, Chen ZT, Li DZ, Duan YZ, Wang ZX and Cao ZH: HSV-TK gene therapy of lung adenocarcinoma xenografts using a hypoxia/radiation dual-sensitive promoter. Ai Zheng 23: 788-793, 2004 (In Chinese).
11. Miyazaki Y, Nakashishi H, Yamamoto K, Li YN, Matsubara H, Mikami K, Okihara K, Kawauchi A, Bonavida B and Miki T: Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J Clin Oncol 23: 448-454, 2005.
12. Pluta P, Cebula-Obrzut B, Ehemann V, Pluta A, Wierzbowska A, PiekarSKI J, Bilski A, Nejc D, Kordek R, Robak T, Smolewski P and Jeziorski A: Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 58: 430-435, 2011.
13. Fulda S, Wick W, Weller M and Debatin KM: Smac agonists sensitize for Apo2L/TRAIL or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815, 2002.
14. Lok CN and Ponka P: Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 274: 24152-24155, 1999.
15. Okino ST, Chichester CH and Whitlock JP Jr: Hypoxia-inducible mammalian gene expression analyzed in vivo at a TATA-driven promoter and at an initiator-driven promoter. J Biol Chem 273: 23873-23843, 1998.
16. Kwon OJ, Kim PH, Huyun S, Wu L, Kim M and Yun CO: A hypoxia- and a-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 16: 6071-6082, 2010.
17. Barnes MN, Coolidge CJ, Hemminki A, Alvarez RD and Curiel DT: Conditionally replicative adenoviruses for ovarian cancer therapy. Mol Cancer Ther 1: 435-439, 2002.
18. Wu JH, Wang HF, Wang ZC, Xu K, Qi YL, Li JH, Gong SL, Liu Y and Liu Y: Conditionally replicating adenovirus combined with gene-targeted radiotherapy induces apoptosis via TRAIL death receptors in MDA-MB-231 cells. Mol Med Rep 8: 299-305, 2013.
19. Dai M, Cui P, Yu M, Han J, Li H and Xiu R: Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J Pineal Res 44: 121-126, 2008.
20. Liu G, Gong P, Zhao H, Wang Z, Gong S and Cai L: Effect of low-level radiation on the death of male germ cells. Radiat Res 165: 379-389, 2006.
21. Yang SW, Chanda D, Coody JJ, Rivera AA, Waehler R, Siegal GP, Douglas JT and Ponnazhagan S: Conditionally replicating adenovirus expressing TIMP2 in creases survival in a mouse model of disseminated ovarian cancer. PLoS One 6: e25131, 2011.
22. Zhang FQ, Xu Y, Yang RJ, Wu B, Tan XH, Qin YD and Zhang QW: Combination effect of oncolytic adenovirus therapy and herps simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta Pharmacol Sin 30: 617-627, 2009.
23. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R and Hanna N: TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 22: 592-601, 2004.
24. Kasuya H, Takeda S, Nomoto S and Nakao A: The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 12: 725-736, 2005.
25. Teysisseur F, Bay JO, Dionet C and Verrelle P: Cell cycle regulation after exposure to ionizing radiation. Bull Cancer 86: 345-357, 1999 (In French).
26. Deplanque G, Céraline J, Mah-Becherel MC, Cazenave JP, Bergerat JP and Klein-Soyer C: Caffeine and the G2/M block element in the transferin receptor gene. J Biol Chem 274: 24147-24152, 1999.
27. Berardi P, Cebula-Obrzut B, Ehemann V, Pluta A, Wierzbowska A, PiekarSKI J, Bilski A, Nejc D, Kordek R, Robak T, Smolewski P and Jeziorski A: Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 58: 430-435, 2011.
28. Guo C, Li Y, Zhang H, Wang Z, Jin M, Zhang L, An L, Hu G, Liu X, Yu Y, Du H and Sun Z: Enhanced expression of antiproliferation and proapoptotic effects of cadmium chloride combined with hSmac in hepatocellular carcinoma cells. Chemotherapy 57: 23-34, 2011.